Callahan, Margaret K. et al
"Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors." Cancer Immunology Research
7.2 Supplement
(2019):
A006.
Web. 17 Jan. 2021.
